We evaluated the epidemiologic evidence that vitamin D may be related to human autoimmune disease risk. Methods: PubMed, limited to English from inception through April 2010, was searched using keywords: "vitamin D," "autoimmune," and autoimmune disease names. We summarized in vitro, animal, and genetic association studies of vitamin D in autoimmune disease pathogenesis. We sorted epidemiologic studies by design and disease and performed a systematic review of (a) cross-sectional data concerning vitamin D level and autoimmune disease; (b) interventional data on vitamin D supplementation in autoimmune diseases; and (c) prospective data linking vitamin D level or intake to autoimmune disease risk. Results: Vitamin D has effects on innate and acquired immune systems, and vitamin D receptor polymorphisms have been associated with various autoimmune diseases. In experimental animal models, vitamin D supplementation can prevent or forestall autoimmune disease. Of 1446 studies identified and screened, 76 studies that examined vitamin D levels in autoimmune disease patients, particularly with active disease, and compared with controls. Nineteen observational or interventional studies assessed the effect of vitamin D supplementation as therapy for various autoimmune diseases (excluding psoriasis and vitiligo) with a range of study approaches and results. The few prospective human studies performed conflict as to whether vitamin D level or intake is associated with autoimmune disease risk. No interventional trials have investigated whether vitamin D affects human autoimmune disease risk. Conclusions: Cross-sectional data point to a potential role of vitamin D in autoimmune disease prevention, but prospective interventional evidence in humans is still lacking.
T he cause of the breakdown in immune tolerance that allows for the development of immunity to self-targets in autoimmune diseases such as rheumatoid arthritis (RA), inflammatory bowel disease, and multiple sclerosis (MS) is unknown. It is hypothesized that environmental exposures, including factors that stimulate endogenous inflammation, trigger the development of autoimmunity in genetically susceptible individuals (1) . Autoimmune diseases cluster within families and within individuals, with many individuals developing more than 1 autoimmune disease (2) (3) (4) . Polymorphisms in several genes have been associated with increased susceptibility to multiple autoimmune diseases (2, (5) (6) (7) (8) . Autoimmune diseases also share epidemiologic risk factors such as cigarette smoking and crystalline silica exposure (9, 10) . Many autoimmune diseases are characterized by activation of the adaptive immune system with associated innate immune cell activation leading to inappropriately elevated levels of widespread systemic inflammation, in particular, tumor necrosis factor-␣ (TNF␣) and interleukins-1 and -6 (IL-1 and IL-6), potent cytokines produced by macrophages and monocytes among other cell types.
The Autoimmune Diseases Coordinating Committee of the National Institutes of Health estimated that 23.5 million Americans were affected by 1 or more autoimmune diseases in 2005 (11) . This number appears to be growing and is almost certainly an underestimate (12) . For unknown reasons, most autoimmune diseases are more common among women than men, although this is less true after menopause (13) . Together, autoimmune diseases are the third leading cause of morbidity in the industrialized world and a leading cause of mortality among women (14, 15) . With the exception of celiac sprue and pernicious anemia, there are no current means for the prevention or cure of most autoimmune diseases. Treatment of autoimmunity often consists of corticosteroids, immunosuppressive agents, and biologic agents that target TNF and other inflammatory cytokines. The 2005 National Institutes of Health report estimated that the annual direct and indirect costs of autoimmune diseases in the U.S. far exceed $100 billion annually (11).
Vitamin D, obtained from diet, supplements, or conversion of 7-dehydrocholesterol in the skin by ultraviolet-B radiation, is hydroxylated in the liver to 25-hydroxyvitamin D [25(OH)D], the major circulating vitamin D metabolite (16, 17) , which is further synthesized by 1␣-hydroxylase to the active form, 1,25-dihydroxyvitamin D [1, 25(OH) 2 D] . Current dietary recommendations are geared only to prevent quite low vitamin D levels. Circulating 1,25(OH) 2 D has a very short halflife and is tightly regulated by parathyroid hormone. Fibroblast growth factor 23, which is produced in osteoblasts, is also important in regulating 1,25(OH) 2 production in the kidney (18) . "Normal" levels for 25(OH)D at most laboratories are Ͼ20 ng/mL. However, at 25(OH)D levels below 30 ng/mL, parathyroid hormone secretion is increased, suggesting that the current "normal" levels for vitamin D are inadequate (19) (20) (21) . Vitamin D deficiency using the current standard for serum 25(OH)D level is relatively common. In 1 study, over 50% of inpatients at Massachusetts General Hospital had low 25(OH)D levels (22) .
Vitamin D is an inexpensive and relatively safe nutritional supplement, widely held to have anti-inflammatory and immunomodulating effects. The purported health benefits of this inexpensive and available dietary supplement have received enormous attention in both the medical literature and the popular press (23) (24) (25) (26) . It has been widely hypothesized that vitamin D deficiency acts as an environmental trigger for the induction of autoimmunity, and that high-dose vitamin D supplementation could be preventive (27) (28) (29) (30) (31) (32) (33) (34) , yet the scientific evidence appears to conflict. The Agency for Healthcare Research and Quality recently performed a systematic review entitled, "Vitamin D and Calcium: A Systematic Review of Health Outcomes," published in August 2009 (35) . The report investigated the published literature regarding serum 25(OH)D or 1,25(OH) 2 D concentrations and multiple disease outcomes, including autoimmune diseases. The review did not include studies investigating sunlight exposure as a source of vitamin D intake nor did it include studies in which dietary intake of vitamin D was assessed without measurement of serum levels, as nutrient composition tables for vitamin D were thought to be inadequate. The report also excluded cross-sectional and retrospective case-control studies where the measure of exposure occurred after or concurrent with the outcome. After these exclusions, no studies were identified that addressed the relationship between vitamin D and incident autoimmune disease. We sought to perform an extensive systematic review of the published literature to evaluate the strength of all types of evidence linking vitamin D intake to the risk of incident autoimmune diseases.
METHODS
We searched the PubMed database from inception through April 2010 restricted to English language and human studies with the following search terms "vitamin D AND"; "autoimmune disease"; "autoimmunity"; "rheumatoid arthritis"; "spondylitis"; "spondyloarthropathy"; "psoriatic arthritis"; "systemic lupus erythematosis"; "scleroderma"; "systemic sclerosis"; "myositis"; "dermatomyositis"; "polymyositis"; "vasculitis"; "polymyalgia rheumatica"; "type 1 diabetes"; "multiple sclerosis"; "autoimmune thyroiditis"; "Graves"; "Hashimoto's"; "inflammatory bowel disease"; "Crohn's disease"; "ulcerative colitis"; "vitiligo"; "autoimmune hepatitis"; "Behcet's"; "uveitis"; "Addison's." We excluded review articles, case reports, and studies primarily related to bone metabolism or osteoporosis (unless they included relevant data on vitamin D and autoimmune disease risk). Studies on the topical and parenteral treatment of psoriasis and vitiligo with vitamin D analogs were beyond the scope of this review and treatment with vitamin D-related compounds has been extensively reviewed in a systematic manner (eg (36) ). In addition, primary biliary cirrhosis and celiac disease were not included in the PubMed search since loss of fat-soluble vitamins is common in these diseases and vitamin D deficiency is highly prevalent in cirrhotics (37) . We also conducted hand searches of reference lists to add to our list of articles.
We aimed to address the following questions: (1) What are the cross-sectional data linking vitamin D to autoimmune disease?; (2) What are the prospective data linking vitamin D to the risk of future autoimmune disease?; and (3) What are the interventional data concerning dietary and/or supplemental vitamin D and risk of autoimmune disease? We carefully reviewed the abstracts of the studies identified and selected those relevant to our questions to perform a systematic review of the strengths and weaknesses of this literature. We included and qualitatively summarized background basic science studies, both in vitro and in animal models, genetic studies, studies of vitamin D's effects on biomarkers of systemic inflammation, as well as ecologic/geographic epidemiologic studies of the incidence or prevalence of autoimmune diseases according to latitude (potentially related to vitamin D from UV light).
To explore the potential for publication bias among studies of vitamin D intake and risk of developing autoimmune disease, a funnel plot was created for these studies by plotting the risk estimates (odds ratios or relative risks) of developing an autoimmune disease in each study (x-axis) against the number of autoimmune cases in each study (y-axis). (A pattern resembling a symmetrical inverted funnel is generally interpreted as showing no significant publication bias, whereas the absence of studies in the lower sections of an inverted funnel, where small studies would lie, implies the presence of publication bias (38) .)
RESULTS
We identified 1446 potentially relevant studies through our literature search and sorted and reviewed them as in Figure 1 . Two hundred forty-two were immediately excluded as irrelevant to this review, leaving 1204 that were reviewed in further detail. Basic science and in vitro studies, genetic studies, ecological studies, and studies of biomarkers of inflammation were reviewed and summarized in the text. The human epidemiologic studies were sorted into epidemiologic studies of vitamin D levels in existing autoimmune disease (See the supplemental Table 2 Studies of Vitamin D Level and Risk of Autoimmune Disease n= 2 Table 3 Studies of Vitamin D Intake and Risk of Autoimmune Disease n= 12 Table 4 Ecological (70) (71) (72) (73) (74) . Treatment with a low calcemic vitamin D analog had a prophylactic as well as therapeutic effect on a murine model of Th1-like colitis (75) . Administration of 1,25(OH) 2 D or its analogs to nonobese diabetic mice modulates the expression of chemokines and cytokines and prevents diabetes (76) . Vitamin D receptor knock- (206) out mice develop severe diarrhea, rectal bleeding, and marked body weight loss, leading to death in 2 weeks. Thus, vitamin D deficiency is thought to compromise the mucosal barrier and increase susceptibility to mucosal damage and potentially the risk of inflammatory bowel disease (77) .
Evidence in Humans: Associations of Vitamin D with Circulating Biomarkers of Systemic Inflammation
Cross-sectional studies in healthy and ill populations suggest potential favorable effects of vitamin D-as measured by circulating 25(OH)D, sun exposure, or dietary or supplement intake-on inflammatory biomarkers (78) (79) (80) . Inverse associations between serum vitamin D levels and serum CRP concentrations have been found in patients with diabetes mellitus, atherosclerotic vascular disease, inflammatory polyarthritis, and prolonged chronic illness (35, 81, 82) . Increased TGF-␤ serum levels were observed when vitamin D was given for a 6-month period to 16 subjects with MS (83) . TNF-␣, interferon-␥, and IL-13 levels, however, did not change after supplementation. In a trial involving 200 overweight subjects enrolled in a weight loss program, participants were randomized to vitamin D (83 g/d) or placebo in a doubleblind manner for 12 months and serum TNF-␣ levels did decrease more in the vitamin D group than in the placebo group marker (10.2% compared with 3.2% decrease; P ϭ 0.049) (84) . In a recent interventional study, 324 adults were assigned to 20,000 IU of vitamin D per week, 40,000 IU vitamin D per week, or placebo. Multiple cytokines, including IL-2, -4, -5, -10, -12, -13, -17, intercellular adhesion molecule-1, interferon-␥, monocyte chemotactic protein-1, and high CRP, were measured at the start and end of 1 year. No significant differences in changes levels of any of these cytokines was detected, nor was there any indication of a polarization of the T cells toward a Th2 dominant type (85) .
Ecologic Associations Implicating Vitamin D in Autoimmune Disease
Evidence comes from ecologic observations that several autoimmune diseases, including inflammatory bowel disease, MS, type I diabetes, and RA, are more prevalent at northern latitudes where sun exposure is reduced (86-92). The strongest ecologic evidence linking vitamin D with autoimmune disease risk is for MS (93) . An increased prevalence of MS at northern, compared with southern, latitudes has long been observed and a strong inverse correlation of MS incidence with UV light exposure is also seen (91, 94) . MS has also been associated with birth during the winter compared with other seasons of the year and it is hypothesized that this could reflect low maternal vitamin D during pregnancy (95) . Last, seasonal variation in MS relapses detected by magnetic resonance imaging has been observed, with increased flares occurring during the winter compared with summer months (96) .
Genetic Polymorphisms in Vitamin D Pathway Genes Associated with Autoimmune Diseases
Polymorphisms in the VDR gene have been associated with increased risk of multiple autoimmune diseases, including Hashimoto's thyroiditis, inflammatory bowel disease, Graves' disease, RA, SLE, primary biliary cirrhosis, autoimmune hepatitis, Addison's disease, vitiligo, celiac disease, and type I diabetes, as well as MS in humans (97) (98) (99) (100) (101) (102) (103) (104) (105) (106) (107) (108) (109) (110) (111) (112) . A vitamin D response element is found in the promoter region of the HLA DRB1*1501 allele, an allele strongly associated with MS susceptibility pathogenesis in Caucasians (112) . However, not all of the polymorphisms associated with autoimmune diseases in past studies have known functional consequences and the strengths of the associations vary. Moreover, not all of these associations have been replicated. There have been 4 case-control studies comparing 25(OH)D and 1,25(OH)D levels in patients with ankylosing spondylitis to healthy controls. A study of 100 AS patients and 58 controls in Turkey found that 25(OH)D levels were lower in patients than controls (137), but an earlier study of 38 AS patients and 52 controls in Germany had not detected a significant difference (138). Two studies by Lange and coworkers have found that 1,25(OH)D levels are lower in ankylosing spondylitis patients and negatively correlated with disease activity, thought possibly related to the high prevalence of osteoporosis seen in this disease (139,140). Seventy-six ankylosing spondylitis patients had significantly lower 25(OH) levels than did 120 psoriatic arthritis patients, and a significant negative correlation between C-reactive peptide levels and 25(OH)D levels was reported in the combined cohort of these patients in a study by Teichmann and coworkers (141).
We found 8 past studies addressing vitamin D levels in patients with scleroderma. Of the 5 case-control studies, 2 demonstrated lower 25(OH)D levels in patients with scleroderma than controls (142,143), and 3 did not (144-146). In 2 case-only analyses, it was found that 25(OH)D levels were, not surprisingly, lower in those with more severe underlying scleroderma, more longstanding disease, more disease activity, more pulmonary hypertension, and lower diffusing lung capacity (147,148). (201) In In MS as well, there have now been several studies reporting that 25(OH)D levels are lower in cases with MS than in healthy controls (162) (163) (164) (165) (166) (167) (168) , and 2 that have not (169, 170) . Lower vitamin D levels have been found in MS patients especially during the summer, compared with winter months (171) , in those with progressive as opposed to relapsing-remitting forms of the disease (172) , and associated with increased disability in MS (163, 166) , and clinical activity and risk of relapse (162, 167, 168, 172) .
Two case-control studies have reported lower 25(OH)D levels in patients with Crohn's disease compared with controls (173, 174) , and 3 of 4 studies have found that levels are lower in those with active inflammatory bowel disease (173) (174) (175) (176) . The only study of the association between vitamin D level and thyroid autoimmunity was conducted in India where a large group of over 600 healthy individuals were screened for antithyroid antibodies. A weak but significant inverse correlation was found between vitamin D level and titer of antithyroid peroxidase autoantibodies (177) . One cross-sectional case-only study of 25(OH)D levels in patients with vitiligo reported apparently low levels, without controlling for season (178) . We found no epidemiologic studies of vitamin D levels in existing pernicious anemia, vasculitis, adult inflammatory myositis, polymylagia rheumatica, Addison's disease, uveitis, or Behcet's disease.
In sum, many, but not all, case-control studies, circulating levels of 25(OH)D and occasionally 1,25(OH) 2 D have been found to be lower in subjects with various autoimmune diseases than in matched healthy controls. The evidence pointing to lower vitamin D levels in existing disease is not equally strong for all autoimmune diseases and some diseases have yet to be studied. The differences between the many similar studies of a specific disease may relate to their different sizes and the heterogeneity in their statistical power, as well as to adjustment for confounding factors. Taken together, it is also apparent from these studies that ethnic origin (179) , season of the year (180), and disability (163, 166) have strong effects on circulating vitamin D levels and it is not clear that all of these crosssectional studies controlled for these important confounders. Additionally, disease activity and disability, glucocorticoid use (132), serum creatinine (132), microalbuminuria (157), ketoacidosis (160, 161) , and use of hydroxychloroquine (135) influence circulating vitamin D levels. Hydroxychloroquine prescribed in several autoimmune diseases may inhibit the conversion of 25(OH)D to 1,25(OH) 2 D (135). Thus, while interesting, the major limitation of these cross-sectional studies is that reverse causation is very likely. Low vitamin D level may be the consequence, not the cause, of active autoimmune disease.
Vitamin D Supplementation and Effects on Existing Disease Activity (Table 2)
Several small open-label studies and interventional trials have tested the effects of supplementation with vitamin D, or its analogs, on the activity of established autoimmune diseases. In a double-blind trial conducted in 1973, oral calciferol (100,000 IU/d) for 1 year was administered to 25 subjects who were compared with 24 subjects who received a placebo. The intervention group had improved hand strength, decreased morning stiffness, and need for analgesics/anti-inflammatory medications and decreased erythrocyte sedimentation rate (181) . In a more recent study, high-dose 1-alpha(OH)D3 (alphacalcidiol) reduced pain and CRP levels in 19 RA subjects in a 3-month open-label trial (182) .
Two small open-label studies of 6 months each have shown some promise for oral alphacalcidol (0.25 g twice/d) and 1,25(OH)D in reducing disease activity and tender joint counts in psoriatic arthritis (183, 184) . In an open-label observational study of 60 SLE patients in Spain who took vitamin D3 supplementation for 2 years, significant improvement was seen in subject fatigue, as measured by a visual analog scale, but not SLE disease activity measures (185) . An ongoing National Institutes of Health sponsored trial is investigating vitamin D supplementation on disease activity and interferon-related cytokine activation ("the interferon signature") in SLE.
Five small trials have now studied the effects of oral calcidiol supplementation on scleroderma, morphea, or linear scleroderma (186) (187) (188) (189) (190) . While earlier open-label studies had shown some benefit, in particular for morphea, the most recent randomized trial found that calcitriol was not more effective than placebo in patients with morphea, and the scleroderma group in that trial (n ϭ 7) was too small to any draw conclusions (190) . On the other hand, randomized trials in Italy and China have now shown that vitamin D supplementation in individuals with latent autoimmune diabetes (autoantibodies highly associated with the development of type 1 diabetes) can forestall the development of type 1 diabetes, although it only temporarily reduces the amount of insulin required (191, 192) .
We found 5 small studies or trials of vitamin D supplementation for MS. Fewer exacerbations of disease were seen among 16 MS patients given calcium, magnesium and vitamin D supplements for 1-2 years in an open-label study in 1986 (193) . In another open-label study of calcium and escalating doses of vitamin D supplementation in 12 MS patients, there did not appear to be an effect on disease progression or activity but the number of gadolinium-enhancing lesions per patient appeared decreased af-ter just 12 weeks (194) . In the largest randomized controlled trial yet, 25 MS subjects were randomized to doses of up to 40,000 IU/d over 28 weeks, followed by 10,000 IU/d for 12 weeks over 52 weeks, and 24 MS subjects were randomized to placebo. While the treatment group appeared to have fewer relapse events, the difference was not statistically significant (P ϭ 0.09) possibly due to insufficient statistical power (195) . Thus far, the studies have been small and inconclusive and larger scale trials are called for.
Last, 1 open-label trial in Eastern Europe has compared the effects of supplementation with 25(OH)D to those of 1,25(OH)D for Crohn's disease and found that 1,25D supplementation was associated with a significantly greater decrease in disease activity (assessed by Crohn's Disease Activity Index) (196) .
Studies to date have mainly been small and mostly open-label and include a range of vitamin D preparations, doses, and durations. However, it appears that vitamin D may have an adjunctive role in amelioration of RA, MS, type I diabetes, and perhaps SLE and Crohn's disease. This evidence addresses the question of whether vitamin D has an effect on established disease, but not on the risk of developing an autoimmune disease de novo.
Epidemiologic Studies of Vitamin D Level and Risk of Developing Autoimmune Disease (Table 3)
In the hierarchy of epidemiologic studies, stronger data for association with susceptibility are afforded by prospective studies. Additionally, prospective studies are able to address the potential role of vitamin D in the pathogenesis of autoimmune disease. The relation between vitamin D serum or plasma level-measured by circulating 25(OH)Dand the incidence of autoimmune diseases have been examined in only 2 prospective observational epidemiologic studies of RA and MS, but not in other autoimmune diseases. Serum 25(OH)D level was not related to future RA risk in a Dutch case-control study examining blood bank samples from 79 individuals who developed RA compared with 79 healthy controls, matched on age, sex, and time of blood donation (197) . To address the question on MS, Munger and colleagues used banked blood samples from Department of Defense military recruits, 257 of whom later developed MS. Higher serum levels of 25(OH)D were associated with a significantly lower risk of incident MS, but only among whites, not blacks nor Hispanics, and the effect was most pronounced for individuals under age 20 (198) .
Epidemiologic Studies of Vitamin D Intake and Risk of Developing Autoimmune Disease (Table 4)
Prospective epidemiologic data on vitamin D intake and the risk of developing autoimmune diseases have been systematically reviewed and summarized in Table 4 . The diseases that have been studied include RA, SLE, type 1 diabetes mellitus, and MS. For RA risk, the data have been somewhat conflicting. In the Iowa Women's Health Study, higher baseline vitamin D intake was associated with decreased risk of subsequent RA (199) . In the Nurses' Health Study, a prospective cohort study involving over 180,000 women with multiple dietary assessments over 20 years, intake of vitamin D was not related to risk of developing either SLE or RA (200) . However, in the same cohort, an inverse relationship was discovered between higher intake of vitamin D from supplements, but not overall dietary intake and lower risk of incident MS up to 20 years later (201) .
Several observational studies have addressed the association between maternal vitamin D intake in pregnancy, lactation, or intake in infancy and early childhood and the risk of developing type 1 diabetes. A meta-analysis of 4 case-control studies (202) (203) (204) was performed in 2008 (205) (omitted from Table 4 due to redundancy). Pooled data from the case-control studies showed that the risk of type 1 diabetes was significantly reduced in infants who were supplemented with vitamin D compared with those who were not supplemented (pooled odds ratio 0.71, 95% CI 0.60 to 0.84). One large birth cohort study prospectively assessed vitamin D supplementation during the first year of life (as part of a ricket's prevention study) and confirmed cases of type 1 diabetes in the children up to 31 years later. They found a strongly protective effect of regular vitamin D supplementation in the first year of life: RR 0.12 (95% CI 0.03-0.510) (206) .
Surrogate markers for the development of type 1 diabetes, glutamic acid decarboxylase, or islet antigen-2 autoantibodies, which are highly associated with type 1 diabetes risk, have been used in a few prospective studies. Two birth cohorts of infants at high genetic risk of type 1 diabetes have investigated relationships between maternal intake of vitamin D during pregnancy and the development of this islet cell autoimmunity. A high maternal dietary intake of vitamin D in foods, but not supplements, assessed after pregnancy by questionnaire, was associated with increased risk of islet cell autoantibodies among the children followed for an average of 4 years in an American birth cohort (207) . A larger prospective birth cohort in Finland has reported no association between maternal vitamin D intake (also assessed postpartum by questionnaire) and risk of type 1 diabetes or islet cell autoantibodies in their high genetic risk offspring, followed up to 4.3 years, however (208) .
Our funnel plot for the studies examining the relationship of vitamin D dietary intake and the risk of the 4 autoimmune diseases that have been studied is shown in Figure 2 . Given the dearth of studies, we have included studies of all 4 autoimmune diseases with substantial heterogeneity in design, exposure assessment, and timing in relation to onset of disease/autoantibodies and outcomes. The plot appears slightly asymmetric, displaying potential publication bias with few small nonprotective studies.
However, given the small number of studies, no conclusions can be drawn.
Potential Causes of Conflicting Results
While the development of an autoimmune response to self-antigens underlies all of these diseases, it is likely that vitamin D is not uniformly involved in the pathogenesis of each and every autoimmune disease and is more important in the etiology of some versus others among them. It is clear that not all autoimmune diseases have been equally studied and for most there is a dearth of evidence addressing the potential effects of vitamin D on autoimmune disease susceptibility. Past case-control studies may have been biased by subject recall; cohort studies may have been underpowered for small effects, and potential confounders such as socioeconomic status may not have been consistently well addressed. Prospective observational studies that rely on dietary intake are hampered by subjects' ability to accurately recall food intake and by inadequate means of assessing vitamin D content of all foods. The inconsistency in epidemiologic data regarding vitamin D intake and risk of autoimmune disease has led to some debate and may result in part from the fact that oral vitamin D intakes in many of the studied populations were too low to produce significant effects, as well as limited within population variability in intakes. The difference between high and low oral intakes in observational studies is generally only 300 to 400 IU/d. Given that a vitamin D 3 The human epidemiologic and interventional evidence, however, is weak. Despite the multitude of crosssectional and case-control studies that demonstrate lower levels of vitamin D among individuals with autoimmune diseases than healthy controls, these studies are not able to address causality. Reverse causality, that the disease process of an autoimmune disease, even in early disease, could lower circulating vitamin D concentration is a likely possibility in these studies. Prospective epidemiologic data on vitamin D status and whether intake level has any effect on the incidence of autoimmune diseases are limited or conflicting. There have been no large randomized trials of high-dose vitamin D supplements for the primary prevention of autoimmune diseases in a general population.
Confirming or refuting that elevated dietary vitamin D intake reduces systemic inflammation and/or the risk of incident autoimmune disease is critical, as no prophylactic therapy currently exists for these diseases. The growing enthusiasm for vitamin D supplementation, however, underscores the need for timely and rigorous testing of this hypothesis before use becomes so prevalent as to render it impossible. To understand the effects of moderate-to high-dose vitamin D supplementation, a high-quality, double-blind randomized controlled trial with a large sample size and long duration and designed specifically to include an assessment of these outcomes in a general population is necessary. (162) 20.e6 Vitamin D and the risk of developing autoimmune disease (178) 20.e8 Vitamin D and the risk of developing autoimmune disease
